Overview

Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical-stage biopharmaceutical company focused on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID.

NASDAQ: MBIO

Change
$0.00 0.00%
Price
$ 3.10
Volume
315,929
Market Cap $ M
124.47
As of July 23, 2019 Close Minimum 20 minute delay.

Contact Information

Mustang Bio, Inc.
2 Gansevoort Street
9th Floor
New York, NY 10014
(781) 652-4500
Investor Relations Contact
IR@mustangbio.com